Company: RNST
Filing Date: 2025-03-12
Form Type: DEF 14A
Source: 0000715072-25-000085
Chunk: 102

Company: RENASANT CORP
Filing Date: 2025-03-12
Form: DEF 14A
Chunk 102
---
 outstanding voting stock at the time of the proposed transaction), of any merger, consolidation or sale or lease of all or substantially all of our assets involving the controlling party. For purposes of the fair price provisions, “substantially all” of our assets means assets having a fair market value or book value, whichever is greater, that is at least 25% of the value of our total assets, as set forth on a balance sheet that is as of a date no more than 45 days prior to the proposed transaction. The elevated approval requirements do not apply if (1) the proposed transaction is approved by a majority of our board of directors or (2) the consideration our shareholders will receive in the proposed transaction meets certain minimum price requirements set forth in the Articles of Incorporation. The “fair price” provision makes it more difficult for a third party to obtain approval of a business combination transaction.

• Under our Articles of Incorporation, the board of directors is authorized to issue, without any further approval from our shareholders, a series of preferred stock with the designations, preferences and relative participating, optional or other special rights, and the qualifications, limitations or restrictions, as the board determines in its discretion. This authorization may operate to provide anti-takeover protection because, in the event of a proposed merger, tender offer or other attempt to gain control of us that the board of directors does not believe is in our or our shareholders’ best interests, the board has the ability to quickly issue shares of preferred stock with certain rights, preferences and limitations that could make the proposed takeover attempt more difficult to complete. Such preferred stock may also be used in connection with the issuance of a shareholder rights plan, sometimes called a “poison pill.”

• Our Bylaws provide that a shareholder may not call a special meeting of shareholders unless such shareholder owns at least 50% of our issued and outstanding stock. This requirement makes it more difficult for a third-party acquiror to call a shareholders’ meeting to vote on corporate matters.

Required Vote. The Authorized Shares Increase Amendment requires the affirmative vote of majority of the votes cast at the annual meeting. Abstentions and broker non-votes will not be counted as votes cast for or against the proposal.

The Authorized Shares Increase Amendment and the Director Exculpation Amendment, discussed immediately below, are separate proposals, and whether our shareholders approve the Director Exculpation Amendment or not will have no effect on the approval of the Authorized Shares Increase Amendment.

| OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMM